COLORADO SPRINGS, Colo., Nov. 4, 2010 /PRNewswire/ -- Cannabis Science, Inc. (OTC Bulletin Board: CBIS), a pioneering US biotech company developing pharmaceutical cannabis products announced today that regardless of the outcome of Proposition 19 in California and other marijuana-related electoral issues throughout the country, it is apparent that that the Cannabis Science FDA clinical trials initiatives are more important than ever, as the demand for the Cannabis Science Pharmaceutical Products for critical ailments may reach an all time high.
Cannabis Science understands that its investors realize the importance of providing FDA cleared Cannabis Science pharmaceutical products for much needed treatments for serious illnesses, such as cancer, AIDS, chronic pain, PTSD, etc. It is unrelated to the efforts to legalize the recreational use of marijuana.
Cannabis Science is implementing its pharmaceutical cannabis product development and quality control standardizations through its licensed commercialization developer Rockbrook Inc. It is currently developing its laboratory for quality control and standardizations, while simultaneously preparing to move forward with our FDA applications.
Cannabis Science Inc., President & CEO, Dr. Robert Melamede, stated, "As we take our medical cannabis formulations through the FDA regulatory processes for confirmations and approvals, the needless human suffering, especially experienced by minorities, the sick, children and the elderly, can end because we will make clear the truth about the unique medical values of cannabis. The only question is how much suffering and death will prohibition cause before it ends and the will of the American people is acknowledged and implemented. Most Americans, regardless of political affiliation, support the availability of medical marijuana."
Richard Cowan stated, " With or without Proposition 19, the Company's focus has been and will remain on submitting our initial Investigative New Drug Applications to the FDA so we can begin formally testing our formulations. Dr. Melamede and I have long advocated the complete legalization of cannabis for adults. However, the company's business model does not depend on any changes in the laws. In fact, we expect that there will be an increased demand for our products and the need for professional standards becomes clear to the patients, the public, and even the politicians."
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
SOURCE Cannabis Science, Inc.